Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

LifeNet Health and DePuy Synthes Launch VertiGraft ACIS VG2: Uniquely Engineered

LifeNet Health and DePuy Synthes have launched VertiGraft ACIS VG2, the first allograft interbody spacer specifically designed for DePuy Synthes’s ACIS instrumentation.

Comprised of a cancellous core and cortical endplates, VertiGraft ACIS VG2 is uniquely engineered to provide mechanical strength, reduce migration, and facilitate early vascularization and bone remodeling.1 It is the latest generation of the VertiGraft portfolio of allograft implants, which have a proven record of clinical effectiveness. A prospective study found 100% fusion rates after 12 months in 74 ACDF patients while facilitating bone growth and remodeling.2

“VertiGraft ACIS VG2 brings together the latest in structural allograft technology with state-of-the-art spinal instrumentation,” said Heather Pierce, General Manager of Global Spine and General Orthopedics at LifeNet Health. “The result is greater efficiency and flexibility for clinicians and effective healing for patients.”

The VertiGraft ACIS VG2 allograft is available in multiple footprints, in both parallel and lordotic configurations to optimize fit, fill, and saggital balance restoration. The cortical endplates provide the necessary strength to support the load of the cervical spine, and the cancellous center allows for early bone and vascular in–growth.1,3 In addition, the chamfered profile is designed for easy insertion. It is processed with LifeNet Health’s Allowash XG® and Preservon® technologies, providing the assurance of medical device-grade sterility with the convenience of room-temperature storage.

Designed and processed by LifeNet Health, VertiGraft ACIS VG2 is available exclusively through DePuy Synthes.


1. Fox B, Gopez A, Sukovich W, and Kerner M. Anterior Cervical Spine Fusion Rates Using a Frozen Laminated Composite Allograft and Plating The Internet Journal of Spine Surgery. 2005; 2(1).
2. Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cervical Fusion. Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.
3. Salter R B. Textbook of Disorders and Injuries of the Musculoskeletal System. 1st ed. Baltimore: Williams & Wilkins; 1970.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy